Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF. (Q35657061)

9 August 2017

Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF. (English)

1 reference

Seyed Latif Mousavi Gargari

9 August 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054617%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Masoumeh Rajabibazl

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054617%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Walead Ebrahimizadeh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054617%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Zahra Javidan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054617%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

9 June 2015

1 reference

Applied Biochemistry and Biotechnology

9 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054617%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054617%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054617%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

1985-1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054617%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12010-015-1695-y

13 June 2020

exact match

0 references

cites work

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

VEGF as a key mediator of angiogenesis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Therapeutic anti-VEGF antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Properties, production, and applications of camelid single-domain antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Camelid immunoglobulins and nanobody technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Bacteriophage vehicles for phage display: biology, mechanism, and application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

A novel nanobody against urease activity of Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Anti-angiogenesis therapy in cancer: current challenges and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Recent advances in anti-angiogenic therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Cancer metabolism: the Warburg effect today

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y

Single domain antibodies: promising experimental and therapeutic tools in infection and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12010-015-1695-Y